Reformulated Rybelsus is renamed to reduce patient confusion

Novo Nordisk has renamed the reformulated version of Rybelsus to Ozempic tablets, a change that took effect January 30, 2026 ^[2]. The company said the switch was meant to make it clear that both the tablet and the injectable Ozempic pen treat type 2 diabetes, while Wegovy, in either its injectable or tablet form, is used for weight management ^[2].

The product being renamed is not the original Rybelsus that has been on the market since 2019. That original version, still sold as Rybelsus, comes in 3 mg, 7 mg, and 14 mg tablets ^[2]. The reformulated product, known internally as the R2 formulation, was approved by the FDA on December 9, 2024, in different strengths: 1.5 mg, 4 mg, and 9 mg tablets ^[2]. It is this newer formulation that now carries the Ozempic tablets name ^[2].

Ozempic tablets are approved to help control blood sugar in adults with type 2 diabetes and to lower the risk of major cardiovascular events, such as heart attack or stroke, in patients with type 2 diabetes who are at high risk ^[2]. Like the earlier Rybelsus formulation, the tablets are taken once a day in the morning, on an empty stomach ^[2]. Common side effects reported in at least 5% of patients include nausea, vomiting, diarrhea, abdominal pain, constipation, and decreased appetite ^[2]. The drug carries a boxed warning about thyroid C-cell tumors, along with other warnings covering pancreatitis, gallbladder disease, and kidney injury from fluid loss ^[2].

The renaming follows a broader pattern in Novo Nordisk's semaglutide lineup. The original injectable Ozempic was first approved in December 2017 ^[2]. Wegovy injection followed in 2021 for weight management ^[2]. In December 2025, the FDA also approved a tablet form of Wegovy, in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths, giving patients an oral weight-management option alongside the injectable pen ^[2]. According to a Drugs.com timeline entry dated February 4, 2026, Novo Nordisk described the tablet as an "Ozempic Pill" set to become available in the US during the second quarter of 2026 ^[2].

Why it matters for patients

The name change does not alter the drug itself. Patients taking the R2 formulation of Rybelsus for type 2 diabetes are now taking a product called Ozempic tablets, with the same 1.5 mg, 4 mg, and 9 mg strengths and the same approved uses ^[2]. The stated goal of the rename is to reduce confusion between the oral and injectable versions of semaglutide sold for diabetes, and to separate those from Wegovy products used for weight management ^[2].

Because brand names appear on prescriptions, insurance records, and pharmacy labels, a name change can affect how refills and insurance approvals are processed. The sources reviewed for this article do not detail the exact administrative steps patients or pharmacies must follow when a product is renamed, so specifics about paperwork, refill timing, or insurance re-verification are not yet known from the available reporting.

What happens next

Separate from the renaming, Novo Nordisk announced a significant reduction in the US list price for Wegovy, Ozempic, and Rybelsus semaglutide medicines on February 24, 2026 ^[2]. The company also said on March 9, 2026, that it was expanding US patient access to its FDA-approved semaglutide medicines through the telehealth company Hims & Hers, describing this as part of a shift in its US GLP-1 business model ^[2]. Drugs.com's timeline also notes an April 23, 2026 update on oral semaglutide's potential use in children and adolescents with type 2 diabetes, an area still under study ^[2].